Regulus Therapeutics plans to conduct initial public offering of stock

Proceeds used for preclinical and clinical development of candidates

By Devika Patel

Knoxville, Tenn., Aug. 17 - Regulus Therapeutics Inc. will price an initial public offering of its common stock, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "RGLS."

The deal will have a 30-day greenshoe.

Lazard Capital Markets, Cowen and Co., BMO Capital Markets, Needham & Co. and Wedbush PacGrow Life Sciences are assisting.

Proceeds will be used for the preclinical and clinical development of Regulus' initial microRNA development candidates, the identification and validation of additional microRNA targets and other general corporate purposes.

The manufacturer of earth-friendly products is based in Wilsonville, Ore.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.